Details

Autor(en) / Beteiligte

• McKay, Rana R
• Bossé, Dominick
• Xie, Wanling
• Wankowicz, Stephanie A M
• Flaifel, Abdallah
• Brandao, Raphael
• Lalani, Aly-Khan A
• Martini, Dylan J
• Wei, Xiao X
• Braun, David A
• Van Allen, Eliezer
• Castellano, Daniel
• De Velasco, Guillermo
• Wells, J Connor
• Heng, Daniel Y
• Fay, Andre P
• Schutz, Fabio A
• Hsu, JoAnn
• Pal, Sumanta K
• Lee, Jae Lyun
• Hsieh, James J
• Harshman, Lauren C
• Signoretti, Sabina
• Motzer, Robert J
• Feldman, Darren
• Choueiri, Toni K

Titel

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma

Ist Teil von

• Cancer immunology research, 2018-07, Vol.6 (7), p.758-765

Ort / Verlag

United States

Erscheinungsjahr

2018

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non-clear cell RCC (nccRCC) or patients with sarcomatoid/rhabdoid differentiation are limited. In this multicenter analysis, we explored the efficacy of PD-1/PD-L1 inhibitors in patients with nccRCC or sarcomatoid/rhabdoid differentiation. Baseline and follow-up demographic, clinical, treatment, and radiographic data were collected. The primary endpoint was objective response rate. Secondary endpoints include time-to-treatment failure (TTF), overall survival (OS), and biomarker correlates. Forty-three patients were included: papillary ( = 14; 33%), chromophobe ( = 10; 23%), unclassified ( = 9; 21%), translocation ( = 3; 7%), and ccRCC with sarcomatoid differentiation ( = 7, 16%). Of those 43 patients, 11 patients (26%) had sarcomatoid and/or rhabdoid differentiation ( = 7 with ccRCC; = 4 nccRCC). Overall, 8 patients (19%) objectively responded, including 4 patients (13%) who received PD-1/PD-L1 monotherapy. Responses were observed in patients with ccRCC with sarcomatoid and/or rhabdoid differentiation ( = 3/7, 43%), translocation RCC ( = 1/3, 33%), and papillary RCC ( = 4/14, 29%). The median TTF was 4.0 months [95% confidence interval (CI), 2.8-5.5] and median OS was 12.9 months (95% CI, 7.4-not reached). No specific genomic alteration was associated with clinical benefit. Modest antitumor activity for PD-1/PD-L1-blocking agents was observed in some patients with nccRCC. Further prospective studies are warranted to investigate the efficacy of PD-1/PD-L1 blockade in this heterogeneous patient population. .